effect of entecavir on Hepatitis B virus-related cirrhosis

ABSTRACT

To explore the efficacy of Entecavir on hepatitis B virus-related decompensated cirrhosis. One Hundred two cases of hepatitis B virus-related decompensated cirrhosis patients were randomly divided into treatment group [N=51] and control group [N=51]. Both groups received conventional treatment, meanwhile treatment group received Entecavir for anti-virus treatment. Comparison of liver function between the two groups was statistically significant [P < 0.01] at week 4, 8 and 12 after antiviral therapy, liver fibrosis contrast of two groups was statistically significant [P < 0.01] at week 4, 8 and 12 after antiviral therapy. Although Entecavir can be effective in treating hepatitis B virus-related decompensated cirrhosis, its resistance and course of treatment need to be further evaluated.